Teriparatide y alendronato en osteoporosis por corticoides


Background Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking.

Methods In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 µg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety.

Results At the last measurement, the mean (±SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2±0.7% vs. 3.4±0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.

Conclusions Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov] .)


Source Information

From the University of Alabama at Birmingham, Birmingham (K.G.S.); College of Physicians and Surgeons, Columbia University, New York (E.S.); Katholieke Universiteit Leuven, Leuven, Belgium (S.B.); and Lilly Research Laboratories, Eli Lilly, Indianapolis (F.M., D.W.D., K.A.T., G.P.D., R.M.).

Address reprint requests to Dr. Saag at the University of Alabama at Birmingham, FOT 820, 1530 Third Ave. S., Birmingham, AL 35294-3408, or at ksaag@uab.edu<!– var u = “ksaag”, d = “uab.edu”; document.getElementById(“em0”).innerHTML = ‘‘ + u + ‘@’ + d + ”//–>.

Full Text of this Article

En PDF 

This entry was posted in Medicamentos and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s